Revolution Medicines surges 38% as pancreatic cancer drug shows breakthrough

Shares of Revolution Medicines surged sharply on Monday after the company reported positive results from a late-stage trial of its experimental pancreatic cancer drug, raising hopes for a potential breakthrough in one of the deadliest forms of the disease.

The stock climbed 38% after the opening bell, extending gains to 69% since the start of the year.

Trial shows significant survival benefit

The company said its once-daily pill, daraxonrasib, delivered statistically significant and clinically meaningful improvements in both progression-free and overall survival compared with standard chemotherapy.

Patients treated with daraxonrasib recorded a median overall survival of 13.2 months, nearly double the 6.7 months seen in those receiving intravenous cytotoxic chemotherapy, which remains the standard of care.

Chief executive Mark Goldsmith described the results as a major step forward.

"These results represent a potentially transformative advance for patients and underscore daraxonrasib's potential to redefine the treatment landscape," he said, adding that the company is moving with urgency toward global regulatory submissions.

In a separate interview, Goldsmith said, “These are dramatic, practice-changing outcomes, and our focus now is moving quickly to bring this potential new treatment option to patients who urgently need new treatment.”

A new approach to a difficult disease

Pancreatic cancer remains one of the most lethal cancers globally, with a five-year survival rate of about 13%.

The disease has historically been treated with chemotherapy, with limited progress in improving outcomes.

Daraxonrasib works by targeting RAS mutations, which drive tumour growth and are present in more than 90% of pancreatic cancer cases.

The late-stage trial included patients with metastatic pancreatic ductal adenocarcinoma, including those with a range of RAS variants and even some without identified mutations.

Goldsmith said the findings mark a shift in how the disease could be treated.

“These results usher in a new era of RAS-targeted medicines for pancreatic cancer, which has been exclusively treated with cytotoxic intravenous chemotherapy,” he said.

The drug was also found to be generally well-tolerated, with a manageable safety profile and no new safety concerns identified during the trial.

Regulatory push and market potential

The company plans to seek approval from the US Food and Drug Administration using a Commissioner’s National Priority Voucher, which allows for an accelerated review process that can take just a few months.

External experts have underscored the significance of the results.

"For patients with metastatic pancreatic cancer, new treatment options are urgently needed to increase survival time and improve quality of life," said Brian Wolpin, the trial’s principal investigator.

Analysts have also pointed to the commercial opportunity.

RBC Capital Markets said investors had set a benchmark of 11-12 months for overall survival in such trials, a threshold that Daraxonrasib has exceeded.

The firm estimates a potential market opportunity of more than $10 billion.

Takeover speculation lingers

The positive data could also reignite interest in the company as a potential acquisition target.

Revolution Medicines has been the subject of takeover speculation in recent months, with AbbVie previously denying reports of talks and separate discussions with Merck reportedly ending earlier this year.

While no deal has materialised, the latest trial results may strengthen the company’s strategic appeal.